US Pharma MarketingScribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs
Scribe Therapeutics files for a Nasdaq IPO under ticker SCTX, testing investor appetite for early-stage biotechs still short of Phase 3 data. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…
Scribe Therapeutics filed for a Nasdaq IPO late Thursday.
The move marks a pivotal moment for the biotech and the gene-editing field. The novel CRISPR enzyme developer was created nine years ...
Source: Endpoints News